A Phase 2 interventional study of lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia, sponsored by Celgene. Completed at 52 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-31.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 5 under way, none of them phase 3. Lenalidomide · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment of the 77 interventional ones that give a count, is one of 10 that started in 2009, is one of 42 in phase 2, and was the 30th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →1 of the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:
Vitebsk Regional Clinical Cancer Centre · Sites in Belarus
Ages 18+
By country, each count listing its studies:
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 55 · Phase 3 3
First in 2002; this study’s year is marked. 10 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 104 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 29 across the 77 interventional studies. Of the 65 that completed or were terminated, 41 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 78 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb: 1 open now, 3 under way, none of them phase 3. Of 19 finished, 6 (32%) have results posted.
Among the 25 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Bristol-Myers Squibb, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2009, is one of 2 in phase 2, and was the 8th registered.
Bristol-Myers Squibb’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 25 in Leukemia, Lymphocytic, Chronic, B-Cell:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and effectiveness of different dose regimens of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
This study's enrollment of 104 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted before Celgene became part of Bristol-Myers Squibb.
Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug
Drug: lenalidomide
Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug
Drug: lenalidomide
Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug
Drug: lenalidomide
Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows: * Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily * Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily * Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity
Number of Participants With Treatment-emergent Adverse Events
Adverse events (AEs) were graded for severity by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 with the exceptions of hematologic toxicities and tumor lysis syndrome, according to the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening or disabling AE Grade 5 = Death The investigator determined the relationship of each AE to study drug based on the timing of the AE and whether other medications, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the observed event.
Time frame: From first dose of study drug to 30 days after the last dose; the maximum duration of treatment was 251, 265, and 267 weeks in the 5 mg, 10 mg, and 15 mg treatment groups respectively.
Overall Response Rate (ORR)
ORR was defined as the percentage of patients with a complete response (CR), CR with incomplete bone marrow (BM) recovery (CRi) or partial response (PR) during treatment. Response was assessed according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines. Per the guidelines, a CR required peripheral blood lymphocytes below 4 x 10\^9/L, absence of lymphadenopathy, no hepatomegaly or splenomegaly, absence of disease and blood counts neutrophils \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L, hemoglobin (hgb) \>11g/dL) and BM at least normocellular for age. CRi = CR with incomplete BM recovery. PR = required at least 2 months from end of treatment, a ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value and either a ≥ 50% reduction in lymphadenopathy or ≥50% reduction of liver enlargement or ≥50% reduction of spleen enlargement plus neutrophils \>1.5 x 10\^9/ or ≥50% increase, platelets \>100 x 10\^9/L or ≥50% increase, hgb 11 g/dL.
Time frame: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
Kaplan-Meier Estimate of Duration of Response
Duration of response (DOR) was defined as the time from the first visit where PR, CRi, or CR was documented to progressive disease (PD). Duration of response was censored at the last date that the participant was known to be progression-free for participants who had not progressed at the time of analysis or who withdrew consent or were lost to follow-up prior to documentation of progression.
Time frame: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
Time to Response
Time to response (TTR) was calculated as the time from randomization to the first documented date of response (PR, CRi or CR) based on iwCLL guidelines for participants with an objective response during the treatment period.
Time frame: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
Kaplan-Meier Estimate of Time to Progression
Time to progression (TTP) was defined as the time from randomization to the first documented progression. For participants who did not progress during the study, TTP was censored at the last adequate response assessment showing evidence of no disease progression.
Time frame: From randomization until the end of the study; maximum time on study was 91 months.
Kaplan-Meier Estimate of Event-Free Survival
Event-free survival (EFS) is the interval between the start of treatment to the first sign of disease progression, or treatment for relapse or death (whichever occurred first). If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.
Time frame: From randomization until the end of the study; maximum time on study was 91 months.
Kaplan-Meier Estimate of Progression Free Survival
Progression-free survival (PFS) was calculated as the time from randomization to the first documented progression or death due to any cause during or after the treatment period, whichever occurred first. The progression date was assigned to the earliest time when any progression is observed without prior missing assessments. If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.
Time frame: From randomization until the end of the study; maximum time on study was 91 months.
Kaplan-Meier Estimate of Overall Survival
Overall survival (OS) was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who had withdrawn consent or were lost to follow-up before death was documented.
Time frame: From randomization until the end of the study; maximum time on study was 91 months.
Participants were randomized at 29 sites from North America and Europe.
| Milestone | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Started | 34 | 35 | 35 |
| Received treatment | 34 | 34 | 35 |
| Completed | 34 | 35 | 35 |
| Not completed | 0 | 0 | 0 |
Adverse events (AEs) were graded for severity by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 with the exceptions of hematologic toxicities and tumor lysis syndrome, according to the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening or disabling AE Grade 5 = Death The investigator determined the relationship of each AE to study drug based on the timing of the AE and whether other medications, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the observed event.
| Participants | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Any adverse events | 34 | 34 | 35 |
| Treatment-related adverse events (TRAE) | 33 | 34 | 32 |
| Grade 3/4 adverse events | 33 | 32 | 34 |
| Treatment-related Grade 3/4 adverse events | 31 | 32 | 30 |
| Grade 5 adverse events | 4 | 4 | 3 |
| Treatment-related Grade 5 adverse events | 2 | 2 | 0 |
| Serious adverse events | 24 | 24 | 27 |
| Treatment-related serious adverse events | 15 | 13 | 20 |
| AE leading to discontinuation of study drug | 21 | 17 | 16 |
| TRAE leading to discontinuation of study drug | 16 | 14 | 13 |
| AE leading to study drug dose reduction only | 8 | 6 | 5 |
| AE leading to study drug dose interruption only | 25 | 24 | 25 |
| AE leading to study drug interruption & reduction | 18 | 26 | 19 |
ORR was defined as the percentage of patients with a complete response (CR), CR with incomplete bone marrow (BM) recovery (CRi) or partial response (PR) during treatment. Response was assessed according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines. Per the guidelines, a CR required peripheral blood lymphocytes below 4 x 10\^9/L, absence of lymphadenopathy, no hepatomegaly or splenomegaly, absence of disease and blood counts neutrophils \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L, hemoglobin (hgb) \>11g/dL) and BM at least normocellular for age. CRi = CR with incomplete BM recovery. PR = required at least 2 months from end of treatment, a ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value and either a ≥ 50% reduction in lymphadenopathy or ≥50% reduction of liver enlargement or ≥50% reduction of spleen enlargement plus neutrophils \>1.5 x 10\^9/ or ≥50% increase, platelets \>100 x 10\^9/L or ≥50% increase, hgb 11 g/dL.
| percentage of participants | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Overall Response Rate (ORR) | 47.1 | 37.1 | 40.0 |
Duration of response (DOR) was defined as the time from the first visit where PR, CRi, or CR was documented to progressive disease (PD). Duration of response was censored at the last date that the participant was known to be progression-free for participants who had not progressed at the time of analysis or who withdrew consent or were lost to follow-up prior to documentation of progression.
| weeks | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Kaplan-Meier Estimate of Duration of Response | 101.1 (60.6 to 239.3) | 35.1 (22.0 to NA) | 88.8 (72.1 to 127.3) |
Time to response (TTR) was calculated as the time from randomization to the first documented date of response (PR, CRi or CR) based on iwCLL guidelines for participants with an objective response during the treatment period.
| weeks | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Time to Response | 16.9 (12.1 to 74.1) | 12.6 (8.4 to 52.1) | 12.7 (12.0 to 147.3) |
Time to progression (TTP) was defined as the time from randomization to the first documented progression. For participants who did not progress during the study, TTP was censored at the last adequate response assessment showing evidence of no disease progression.
| weeks | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Kaplan-Meier Estimate of Time to Progression | 96.3 (20.6 to 251.3) | 47.6 (31.9 to 261.1) | 66.3 (20.1 to 89.3) |
Event-free survival (EFS) is the interval between the start of treatment to the first sign of disease progression, or treatment for relapse or death (whichever occurred first). If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.
| weeks | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Kaplan-Meier Estimate of Event-Free Survival | 25.6 (16.1 to 77.6) | 31.9 (21.1 to 47.6) | 24.1 (13.4 to 66.3) |
Progression-free survival (PFS) was calculated as the time from randomization to the first documented progression or death due to any cause during or after the treatment period, whichever occurred first. The progression date was assigned to the earliest time when any progression is observed without prior missing assessments. If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.
| weeks | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Kaplan-Meier Estimate of Progression Free Survival | 31.4 (16.1 to 96.3) | 45.1 (22.4 to 120.1) | 66.3 (16.1 to 89.3) |
Overall survival (OS) was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who had withdrawn consent or were lost to follow-up before death was documented.
| weeks | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| Kaplan-Meier Estimate of Overall Survival | 161.0 (64.9 to 209.0) | 106.7 (83.4 to 235.7) | 154.6 (80.9 to 214.7) |
Collected over From first dose of study drug to 30 days after the last dose; the maximum duration of treatment was 251, 265, and 267 weeks in the 5 mg, 10 mg, and 15 mg treatment groups respectively.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide 5 mg | 24/34 (70.6%) | 24/34 (70.6%) | 34/34 (100%) |
| Lenalidomide 10 mg | 23/34 (67.6%) | 24/34 (70.6%) | 34/34 (100%) |
| Lenalidomide 15 mg | 26/35 (74.3%) | 27/35 (77.1%) | 35/35 (100%) |
| Event | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| PNEUMONIAInfections and infestations | 5/34 | 4/34 | 10/35 |
| TUMOUR FLARENeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/34 | 0/34 | 6/35 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 2/34 | 4/34 | 4/35 |
| ABDOMINAL PAINGastrointestinal disorders | 0/34 | 3/34 | 0/35 |
| HYPERCALCAEMIAMetabolism and nutrition disorders | 3/34 | 0/34 | 2/35 |
| NEUTROPENIABlood and lymphatic system disorders | 1/34 | 2/34 | 3/35 |
| PYREXIAGeneral disorders | 2/34 | 1/34 | 2/35 |
| BACTERAEMIAInfections and infestations | 2/34 | 0/34 | 0/35 |
| PNEUMOCYSTIS JIROVECII PNEUMONIAInfections and infestations | 0/34 | 2/34 | 0/35 |
| SQUAMOUS CELL CARCINOMA OF SKINNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/34 | 1/34 | 1/35 |
| Event | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg |
|---|---|---|---|
| NEUTROPENIABlood and lymphatic system disorders | 25/34 | 30/34 | 26/35 |
| THROMBOCYTOPENIABlood and lymphatic system disorders | 17/34 | 25/34 | 21/35 |
| FATIGUEGeneral disorders | 18/34 | 17/34 | 23/35 |
| TUMOUR FLARENeoplasms benign, malignant and unspecified (incl cysts and polyps) | 17/34 | 21/34 | 23/35 |
| ANAEMIABlood and lymphatic system disorders | 11/34 | 18/34 | 15/35 |
| DIARRHOEAGastrointestinal disorders | 14/34 | 18/34 | 16/35 |
| PYREXIAGeneral disorders | 12/34 | 15/34 | 16/35 |
| RASHSkin and subcutaneous tissue disorders | 9/34 | 8/34 | 16/35 |
| NAUSEAGastrointestinal disorders | 10/34 | 15/34 | 11/35 |
| COUGHRespiratory, thoracic and mediastinal disorders | 10/34 | 15/34 | 12/35 |
| Age, Continuous(years) | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg | Total |
|---|---|---|---|---|
| Mean | 64.0 ± 9.46 | 63.3 ± 8.31 | 63.7 ± 7.56 | 63.6 ± 8.39 |
| Age, Customized(Participants) | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg | Total |
|---|---|---|---|---|
| < 65 years | 16 | 19 | 17 | 52 |
| ≥ 65 years | 18 | 16 | 18 | 52 |
| Sex: Female, Male(Participants) | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg | Total |
|---|---|---|---|---|
| Female | 8 | 13 | 11 | 32 |
| Male | 26 | 22 | 24 | 72 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide 5 mg | Lenalidomide 10 mg | Lenalidomide 15 mg | Total |
|---|---|---|---|---|
| White | 31 | 30 | 33 | 94 |
| Black or African American | 2 | 4 | 2 | 8 |
| Other | 0 | 1 | 0 | 1 |
| Unknown | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2009 to primary completion in Sep 2017, 94 months.
Results were first posted in Oct 2018, 1 year after primary completion.
Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 94 months is above that.
Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell →